Ryan Zubricky, MD

Vitreoretinal Surgery Fellow · Henry Ford Hospital, Detroit, MI

rdzubricky@gmail.com
ryanzubrickymd.com

EDUCATION AND TRAINING

2026–2028	**Vitreoretinal Surgery Fellowship** Henry Ford Hospital, Detroit, MI
2022–2026	**Ophthalmology Residency** Geisinger Medical Center, Danville, PA
2018–2022	**Doctor of Medicine** Northeast Ohio Medical University (NEOMED), Rootstown, OH
2016–2018	**BS, Integrated Life Sciences, summa cum laude** Kent State University, Kent, OH

LICENSURE

Current	**Medical license, State of Michigan**

HONORS AND AWARDS

2025	**Vit-Buckle Society Travel Grant** Austin, TX
2025	**Mid-Year Forum Advocacy Ambassador, Pennsylvania Academy of Ophthalmology** Washington, DC
2018	**Summa Cum Laude** Kent State University
2016	**Trustee Scholarship** Kent State University

RESEARCH EXPERIENCE

2024–2025	**Retina Foundation Research Fellow** Retina Associates of Cleveland, Inc.
2022	**Medical Student Research** Case Western Reserve University / University Hospitals Department of Ophthalmology
2020–2022	**Medical Student Clinical Research** Retina Associates of Cleveland, Inc.
2018–2019	**Laboratory Research Assistant, NEOMED Summer Research Fellow** Inman Research Lab, Northeast Ohio Medical University

PEER-REVIEWED PUBLICATIONS · 11, 6 as first author

1. **Zubricky R**, Ensor W. Acute macular neuroretinopathy following COVID-19 infection: a case report. *Cureus. 2025;17(1):e78182.* doi:10.7759/cureus.78182

2. **Zubricky R**, Miller C, Sciulli H, Coney J, Goduni L, Hull T, Lewis S, Nothnagel A, Novak M, Pendergast S, Pham H, Platt S, Rao L, Schartman J, Singerman L, Tsai T, Wilker S, Miller D. Incidence of recurrent choroidal neovascularization following treatment with pegcetacoplan for geographic atrophy in exudative age-related macular degeneration patients with inactive choroidal neovascularization. *Arch Ophthalmol Optom. 2025;6(1):1-7.* doi:10.22259/2638-5120.0601001

3. **Zubricky R**, Sciulli H, Shannon L, Hensley S, Coney J, Goduni L, Hull T, Pham H, Platt S, Rao L, Schartman J, Miller D. First-year fellow single surgery success rate in primary rhegmatogenous retinal detachments. *Arch Ophthalmol Optom. 2025;6(1).* doi:10.22259/2638-5120.0601002

4. **Zubricky R**, Vrabec T. Accessory fovea in human eye. *Ophthalmol Retina. Published online September 19, 2024.* doi:10.1016/j.oret.2024.08.012

5. Tabbaa T, Mehra AA, Kesav NP, Mahajan VB, Swanson RD, **Zubricky R**, Sobol WM. Autosomal dominant neovascular inflammatory vitreoretinopathy with CAPN5 c.731T>C gene mutation; clinical management of a family cohort and review of the literature. *Ophthalmic Genet. 2023;44(6).* doi:10.1080/13816810.2023.2255257

6. Coney JM, McCoy JE, Buxy Sinha S, Sonbolian N, Zhou L, Hull TP, Lewis SA, Miller DG, Novak MA, Pendergast SD, Pham H, Platt SM, Rao LJ, Schartman JP, Singerman LJ, Donkor R, Fink M, **Zubricky R**, Karcher H. One-year and 18-month outcomes in nAMD patient eyes switched to brolucizumab alone versus to brolucizumab alternating with other anti-VEGF agents. *Clin Ophthalmol. 2023;17:3601-3611.* doi:10.2147/OPTH.S432957

7. **Zubricky R**, McCoy J, Donkor R, Miller DG, Sonbolian N, Heaney A, Bilano V, Karcher H, Coney JM. Real-world frequency and management of ocular adverse events in eyes with neovascular age-related macular degeneration treated with brolucizumab. *Ophthalmol Ther. 2023;12(5):2397-2408.* doi:10.1007/s40123-023-00741-w

8. Peterson J, **Zubricky R**, Matharu K, Prakash G. LASIK flap dislocation masquerading as corneal abrasion: lessons and pearls. *J Emerg Med. 2023;65(2):e137-e139.* doi:10.1016/j.jemermed.2023.04.010

9. Coney J, **Zubricky R**, Sinha Buxy S, Sonbolian N, Zhou L, Hull T, Lewis S, Miller D, Novak M, Pendergast S, Pham H, Platt S, Rao L, Schartman J, Singerman L, Donkor R, Fink M, McCoy J, Karcher H. Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration. *Int J Retina Vitreous. 2023;9:8.* doi:10.1186/s40942-023-00445-0

10. **Zubricky R**, Platt S. Comparison of face-down positioning durations following silicone oil tamponade. *Ophthalmic Surg Lasers Imaging Retina. 2022;53(5):285-292.* doi:10.3928/23258160-20220415-02

11. Harun-Or-Rashid M, Pappenhagen N, **Zubricky R**, Coughlin L, Jassim AH, Inman DM. MCT2 overexpression rescues metabolic vulnerability and protects retinal ganglion cells in two models of glaucoma. *Neurobiol Dis. 2020;141:104944.* doi:10.1016/j.nbd.2020.104944

ONLINE ARTICLES

1. **Zubricky R**, Abdulaal M, Coney J. Brolucizumab. *EyeWiki. American Academy of Ophthalmology; August 2021.* https://eyewiki.org/Brolucizumab

2. **Zubricky R**D, Das JM. Neuroanatomy, superior colliculus. *StatPearls. StatPearls Publishing; updated June 17, 2019.* https://www.ncbi.nlm.nih.gov/books/NBK544224/

ORAL PRESENTATIONS

1. **Zubricky R**. Unmasking the unusual: a case-based approach to ocular disease. *Geisinger Eye Institute (East) Fall 2025 Conference, Vision 2025: Emerging Strategies for Diagnosing and Managing Ocular Conditions. Wilkes-Barre, PA; September 7, 2025.*
2. **Zubricky R**. Different strokes for different folks: a review of ophthalmic strokes. *Ophthalmic Allied Personnel Continuing Education Update. Danville, PA; November 9, 2024.*
3. **Zubricky R**. Posterior uveitis case presentation. *Geisinger Eye Institute (East) Fall 2024 Conference, From Seeing It All to Saving Sight: A Comprehensive Eyecare Conference. Wilkes-Barre, PA; September 8, 2024.*
4. Coney J, **Zubricky R**. Peer-to-peer brolucizumab case review. *Novartis Global Peer-to-Peer Medical Education; September 2021.*

POSTERS

1. **Zubricky R**, Miller C, Sciulli H, Miller A, Goduni L, Hull T, Lewis S, Nothnagel A, Novak M, Pendergast S, Pham H, Platt S, Rao L, Schartman J, Singerman L, Tsai T, Wilker S, Coney J, Miller D. Characteristics of patients with inactive choroidal neovascularization treated with pegcetacoplan for geographic atrophy. *Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Salt Lake City, UT; May 4, 2025.*
2. **Zubricky R**, Miller C, Sciulli H, Coney J, Goduni L, Hull T, Lewis S, Nothnagel A, Novak M, Pendergast S, Pham H, Platt S, Rao L, Schartman J, Singerman L, Tsai T, Wilker S, Miller D. Incidence of recurrent choroidal neovascularization following treatment with pegcetacoplan for macular atrophy in exudative AMD patients with inactive CNV. *Vit-Buckle Society Annual Meeting. Austin, TX; March 20-23, 2025.*
3. **Zubricky R**, Marks S. Bilateral multifocal subretinal fluid: a case report. *Atlantic Coast Retina Club Annual Meeting, Johns Hopkins University. Baltimore, MD; January 8, 2025.*
4. **Zubricky R**, Miller A, Sciulli H, Miller C, Coney J, Hull T, Lewis S, Nothnagel A, Novak M, Pendergast S, Pham H, Platt S, Rao L, Schartman J, Singerman L, Wilker S, Goduni L, Tsai T, Miller D. Real-world experience over 18 months of pegcetacoplan use in a large retinal practice. *American Academy of Ophthalmology (AAO) Annual Meeting. Chicago, IL; October 18-21, 2024.*
5. Peterson J, **Zubricky R**, Matharu K, Prakash G. It's just a corneal abrasion, or is it? Lessons and pearls for emergency room triage in 2 cases of post-LASIK flap dislocation. *American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. San Diego, CA; May 5-8, 2023.*
6. **Zubricky R**, Gupta A, Ensor W. Acute macular neuroretinopathy following COVID-19 infection: a case report. *Geisinger Scholarship Days. Danville, PA; May 2, 2023.*
7. McCoy J, **Zubricky R**, Sinha Buxy S, Sonbolian N, Zhou L, Donkor R, McCrossin C, Miller D, Pham H, Schartman J, Rao L, Singerman L, Novak M, Pendergast S, Karcher H, Coney J. Real-world frequency and outcomes of intraocular inflammation-related adverse events in eyes with neovascular age-related macular degeneration treated with brolucizumab. *ARVO Annual Meeting. New Orleans, LA; April 25, 2023.*
8. **Zubricky R**, McCoy J, Sinha Buxy S, Sonbolian N, Zhou L, Donkor R, McCrossin C, Miller D, Pham H, Schartman J, Rao L, Singerman L, Novak M, Pendergast S, Karcher H, Coney J. Injection intervals in real-world neovascular age-related macular degeneration (nAMD) switch brolucizumab (BROL) patients with at least 12 months of follow-up. *ARVO Annual Meeting. Denver, CO; May 2, 2022.*

9. McCoy J, **Zubricky R**, Sinha Buxy S, Sonbolian N, Zhou L, Donkor R, McCrossin C, Miller D, Pham H, Schartman J, Rao L, Singerman L, Novak M, Pendergast S, Karcher H, Coney J. Characterization of real-world neovascular age-related macular degeneration (nAMD) switch patients treated with brolucizumab (BROL) alternating with other anti-vascular endothelial growth factors (VEGF) versus brolucizumab alone. *ARVO Annual Meeting. Denver, CO; May 2, 2022.*
10. Tabbaa T, Kesav N, Swanson R, **Zubricky R**, Sobol W. Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV): a case series with multimodal imaging. *Ohio Ophthalmological Society Annual Meeting. Columbus, OH; February 19, 2022.*
11. **Zubricky R**, McCoy J, Sinha Buxy S, Sonbolian N, Zhou L, Donkor R, McCrossin C, Miller D, Pham H, Schartman J, Rao L, Singerman L, Novak M, Pendergast S, Karcher H, Coney J. Injection intervals in real-world neovascular age-related macular degeneration (nAMD) switch brolucizumab (BROL) patients with at least 12 months of follow-up. *Ohio Ophthalmological Society Annual Meeting. Columbus, OH; February 19, 2022.*
12. **Zubricky R**, Platt S. Facedown positioning duration for silicone oil tamponade and the effect on retinal re-detachment. *ARVO Annual Meeting; 2021.*
13. **Zubricky R**, Platt S. Effect of facedown positioning for silicone oil tamponade on retinal re-detachment. *Northeast Ohio Medical University Student Research Symposium. Rootstown, OH; November 20, 2020.*
14. **Zubricky R**, Pappenhagen N, Jassim AH, Inman DM. Viral-induced upregulation of monocarboxylate transporter 2 displays protection of retinal ganglion cells in glaucoma. *NEOMED Summer Research Fellowship Poster Day. Rootstown, OH; August 19, 2019.*
15. Campanelli J, **Zubricky R**, Agarwal S, McMullen AM, Jassim AH, Shalwitz R, Inman DM. Impact of ADP-ribose analog INV-102 on retinal ganglion cell transport function in glaucoma. *Kent State University Undergraduate Research Symposium. Kent, OH; April 9, 2019.*